4.618
Schlusskurs vom Vortag:
$4.26
Offen:
$4.27
24-Stunden-Volumen:
349.03K
Relative Volume:
0.92
Marktkapitalisierung:
$111.62M
Einnahmen:
$68.38M
Nettoeinkommen (Verlust:
$-20.17M
KGV:
-5.2246
EPS:
-0.8839
Netto-Cashflow:
$-14.13M
1W Leistung:
+24.14%
1M Leistung:
+71.50%
6M Leistung:
-40.17%
1J Leistung:
-29.84%
Exagen Inc Stock (XGN) Company Profile
Firmenname
Exagen Inc
Sektor
Branche
Telefon
(760) 560-1501
Adresse
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
XGN
Exagen Inc
|
4.62 | 102.92M | 68.38M | -20.17M | -14.13M | -0.8839 |
|
TMO
Thermo Fisher Scientific Inc
|
448.96 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
173.03 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
557.96 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
|
WAT
Waters Corp
|
339.70 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
|
A
Agilent Technologies Inc
|
115.52 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-11 | Eingeleitet | B. Riley Securities | Buy |
| 2025-07-30 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | Eingeleitet | Craig Hallum | Buy |
| 2022-08-05 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-04-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cowen | Outperform |
| 2019-10-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Exagen Inc Aktie (XGN) Neueste Nachrichten
Exagen Inc. (XGN) Inches Lower as Shares Test Key Support Near $4.05Elliott Wave Entry - Newser
Exagen Inc. Common Stock (XGN) Stock Price Today & Analysis - Gotrade
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Per Share - Newser
Earnings call transcript: Exagen Inc. beats Q1 2026 expectations, stock surges - Investing.com Nigeria
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
Exagen Inc stock (US30063K1051): 13G filing shows 9.9% stake - AD HOC NEWS
EXAGEN (XGN) holder Jorey Chernett reports 2.41M shares, 9.9% - Stock Titan
Exagen (XGN) Rallies +8.02% as Bulls Target $3.96 2026-05-19Professional Trade Ideas - Newser
Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time - MSN
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
Why Exagen (XGN) Just Dropped -4.55% — What to Watch 2026-05-15TPO Profile - Newser
Exagen Company Profile & Introduction - Moomoo
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Exagen Targets $73 Million Revenue for 2026 as Test Volumes Surge - HarianBasis.co
Exagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Exagen (XGN) Receives a Buy from BTIG - The Globe and Mail
TradingKey - TradingKey
Exagen Achieves Record Q1 Revenue Driven by AVISE CTD Adoption - HarianBasis.co
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Liquidia Technologies (LQDA) - The Globe and Mail
Exagen (XGN) Q1 2026 Earnings Transcript - AOL.com
Exagen Inc stock (US30063K1051): Q1 revenue hits record $17.3M, up 12% - AD HOC NEWS
XGN Maintained by BTIG -- Price Target Lowered to $8.00 - GuruFocus
CCORF Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
BTIG Maintains Exagen(XGN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Exagen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Exagen stock price target lowered to $8 by BTIG on valuation - Investing.com UK
Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid Challenges - GuruFocus
Exagen (XGN) Reports Record Q1 Revenue of $17.3 Million, Up 12% Year-Over-Year - GuruFocus
Exagen | 10-Q: Q1 2026 Earnings Report - Moomoo
Number of shareholders of Exagen, Inc. – FWB:E08A - TradingView
Exagen Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-05-12 - Seeking Alpha
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Is Exagen (XGN) 30.9% Overvalued After Q1 2026 Earnings? EPS -0. - GuruFocus
Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Exagen Q1 earnings call highlights - MSN
Exagen Q1 Earnings Call Highlights - MarketBeat
XGN Maintains Revenue Forecast for 2026 - GuruFocus
Exagen Inc. Achieves Record $17.3 Million Q1 2026 Revenue - HarianBasis.co
Exagen (XGN) Achieves Strong Q1 Revenue Exceeding Expectations - GuruFocus
Exagen (NASDAQ:XGN) Issues Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
Exagen Inc. Reaffirms Earnings Guidance for the full year 2026 - marketscreener.com
Finanzdaten der Exagen Inc-Aktie (XGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exagen Inc-Aktie (XGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ABALLI JOHN | President and CEO |
Feb 24 '26 |
Sale |
3.61 |
11,430 |
41,262 |
702,997 |
| Black Jeffrey G. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.61 |
1,584 |
5,718 |
267,442 |
| ABALLI JOHN | President and CEO |
Oct 16 '25 |
Sale |
11.82 |
31,787 |
375,598 |
714,427 |
| Black Jeffrey G. | Chief Financial Officer |
Sep 02 '25 |
Sale |
9.79 |
20,466 |
200,362 |
269,026 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):